These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 34372782)

  • 1. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.
    Mostaza JM; Suarez C; Cepeda JM; Manzano L; Sánchez D;
    BMC Cardiovasc Disord; 2021 Aug; 21(1):384. PubMed ID: 34372782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
    Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
    Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation.
    Contreras Muruaga MDM; Vivancos J; Reig G; González A; Cardona P; Ramírez-Moreno JM; Martí J; Suárez Fernández C;
    J Comp Eff Res; 2017 Jun; 6(4):303-312. PubMed ID: 28353372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
    Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
    J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
    Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
    Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands.
    Chen Q; Toorop MMA; Tops LF; Lijfering WM; Cannegieter SC
    JAMA Netw Open; 2023 Apr; 6(4):e239973. PubMed ID: 37097630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation.
    Douros A; Renoux C; Yin H; Filion KB; Suissa S; Azoulay L
    Am J Med; 2019 Feb; 132(2):191-199.e12. PubMed ID: 30691551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study.
    Suárez Fernández C; Mostaza JM; Castilla Guerra L; Cantero Hinojosa J; Suriñach JM; Acosta de Bilbao F; Tamarit JJ; Diaz Diaz JL; Hernandez JL; Cazorla D; Ràfols C;
    Med Clin (Barc); 2018 Jul; 151(1):8-15. PubMed ID: 28992980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.
    Ferroni E; Gennaro N; Costa G; Fedeli U; Denas G; Pengo V; Corti MC
    Int J Cardiol; 2019 Aug; 288():72-75. PubMed ID: 31043323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
    Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
    Renoux C; Coulombe J; Suissa S
    BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry.
    Gullón A; Suárez C; Díez-Manglano J; Formiga F; Cepeda JM; Pose A; Camafort M; Castiella J; Rovira E; Mostaza JM;
    Med Clin (Barc); 2017 Mar; 148(5):204-210. PubMed ID: 27993408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB; Fogerty AE
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation.
    Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L
    JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
    Elvira Ruiz G; Caro Martínez C; Flores Blanco PJ; Cerezo Manchado JJ; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Pascual Figal DA; Bailén Lorenzo JL; Manzano-Fernández S
    Eur J Clin Invest; 2019 Oct; 49(10):e13161. PubMed ID: 31449685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation.
    Abrahami D; Renoux C; Yin H; Fournier JP; Azoulay L
    Thromb Haemost; 2020 Oct; 120(10):1384-1394. PubMed ID: 32717756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.